ISELIN, NJ, March 13, 2023 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it is aware that the Federal Deposit Insurance Corp. the Silicon Valley Bank (“SVB”).
Outlook Therapeutics does not hold any deposits or investments in SVB.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO . The FDA accepted Outlook Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29, 2023. The submission is supported by Outlook Therapeutics’ wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THEE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in the treatment of retinal diseases in the United States, United Kingdom, Europe, Japan, and others other markets. As part of the Company’s multi-year commercial planning process, and in anticipation of potential FDA approval in August 2023, Outlook Therapeutics and AmerisourceBergen have entered into a strategic commercialization agreement to expand the Company’s reach for connecting retina specialists and their patients. AmerisourceBergen will provide third-party logistics (3PL) distribution and services, as well as pharmacovigilance services in the United States. For more information, please visit www.outlooktherapeutics.com.
CONTACTS:
Media Questions:
Harriet Ullman
Vice president
LaVoie Health Science
Q: 617-669-3082
hullman@lavoiehealthscience.com
Investor Questions:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
Q: 833.475.8247
OTLK@jtcir.com
